Jeffrey W. Scott

Data processor with branch control and procedures

John H. Arends, Lea Hwang Austin Lee, William C. Moyer, 1999 .

Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

Jeffrey W. Scott, Y. Lau, D. Song, 2016, Journal of clinical pharmacology.

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors

Manish R. Patel, Jeffrey W. Scott, H. Tawbi, 2016, Cancer Chemotherapy and Pharmacology.

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors

Jeffrey W. Scott, Sunil Sharma, C. Britten, 2014, Cancer Chemotherapy and Pharmacology.

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

Jeffrey W. Scott, K. Bhalla, D. DeAngelo, 2009, British journal of haematology.

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

Jeffrey W. Scott, Sunil Sharma, H. Burris, 2014, Investigational New Drugs.

Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors

de Elisabeth G. E. Vries, Jeffrey W. Scott, H. Burris, 2008 .

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Jeffrey W. Scott, K. Bhalla, D. DeAngelo, 2007 .

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.